Gulapa Kridsanai, Eksombatchai Dararat, Petnak Tananchai, Boonsarngsuk Viboon
Division of Pulmonary Medicine and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Infect Drug Resist. 2024 Oct 29;17:4727-4732. doi: 10.2147/IDR.S479764. eCollection 2024.
COVID-19 infection is associated with an increased risk of severe illness and adverse outcomes in individuals with immunocompromising conditions. Immunocompromised patients may have difficulty with viral clearance, which can lead to persistent infection and potential relapses in viral replication.
Herein, we present four cases of persistent COVID-19 pneumonia in immunocompromised patients, including those with diffuse large B-cell lymphoma, polyarteritis nodosa, and end-stage renal disease post-kidney transplant. Three patients had previously received rituximab. Notably, all patients in this cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (IgG) and negative anti-nucleocapsid IgG values.
Persistent COVID-19 infection should be considered in the differential diagnosis of immunocompromised patients who exhibit ongoing symptoms or lack of improvement in chest X-ray findings following initial COVID-19 treatment. Early recognition, beyond the diagnosis of post-COVID organizing pneumonia, may significantly improve clinical outcomes with timely and appropriate treatment.
新型冠状病毒肺炎(COVID-19)感染会增加免疫功能低下个体患重症和不良结局的风险。免疫功能低下的患者可能在病毒清除方面存在困难,这可能导致持续感染以及病毒复制的潜在复发。
在此,我们报告了4例免疫功能低下患者的持续性COVID-19肺炎病例,包括弥漫性大B细胞淋巴瘤、结节性多动脉炎以及肾移植术后终末期肾病患者。3例患者先前接受过利妥昔单抗治疗。值得注意的是,该队列中的所有患者抗受体结合域免疫球蛋白G(IgG)呈阳性,而抗核衣壳IgG值呈阴性。
对于初次COVID-19治疗后仍有持续症状或胸部X线检查结果无改善的免疫功能低下患者,鉴别诊断时应考虑持续性COVID-19感染。除了诊断COVID-19后机化性肺炎之外,早期识别可能通过及时、恰当的治疗显著改善临床结局。